ClinicalTrials.gg
Not yet recruitingNCT07938931LOGICALUpdated Nov 16, 2026

Low Tidal Volume Strategy In Cardiogenic Pulmonary Edema: The Logical Trial

An interventional study of Low tidal volume ventilation strategy and Intermediate tidal volume ventilation strategy in Cardiogenic Pulmonary Oedema, Acute Hypoxemic Respiratory Failure and Ventilator-Induced Lung Injury, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Not applicable, Interventional, and Supportive care

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.

The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.

The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.

02

Conditions studied

  • Cardiogenic Pulmonary Oedema
  • Acute Hypoxemic Respiratory Failure
  • Ventilator-Induced Lung Injury
03

In context

Respiratory Insufficiency

1,370 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.

This study's planned enrollment of 300 is above the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Admission to a participating intensive care unit (ICU).
  2. Within the first 24 hours of invasive mechanical ventilation, whether ventilation was started before or after admission to the participating ICU.
  3. Expected duration of invasive mechanical ventilation greater than 24 hours.
  4. Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:

    1. PaO2/FiO2 ratio below 300 mmHg.
    2. Pulmonary congestion shown by at least one of the following:

      • Lung ultrasound showing multiple B-lines (at least 3 per zone), distributed bilaterally in at least 2 zones per hemithorax; or
      • Chest radiograph showing interstitial or alveolar edema, vascular redistribution, or Kerley B-lines.
    3. Evidence of a cardiogenic origin shown by at least one of the following:

      • Echocardiographic evidence of elevated left-sided filling pressures (E/e' >14 or E/A >2); or
      • Pulmonary capillary wedge pressure >15 mmHg measured with a pulmonary artery catheter.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another interventional clinical trial.
  2. More than 24 hours of invasive mechanical ventilation.
  3. Extracorporeal support already initiated.
  4. Expected extubation within the next 24 hours.
  5. A predominantly noncardiogenic cause of acute respiratory failure, including acute respiratory distress syndrome, active pneumonia or other pulmonary infection, confirmed pulmonary embolism, or acute lung injury of noncardiac origin.
  6. Pregnancy.
  7. Risk of or suspected elevated intracranial pressure.
  8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV .
  9. Known pre-existing interstitial lung disease.
  10. Previous pneumonectomy or lobectomy.
  11. Terminal condition, a decision to limit life-sustaining treatment, or a do-not-resuscitate order.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Low Tidal Volume Ventilation

    Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance.

    Procedure: Low tidal volume ventilation strategy

  • Active comparator
    Intermediate Tidal Volume Ventilation

    Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits.

    Procedure: Intermediate tidal volume ventilation strategy

Interventions

  • ProcedureLow tidal volume ventilation strategy

    Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance.

  • ProcedureIntermediate tidal volume ventilation strategy

    Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O.

06

What researchers measure

Primary outcomes

  1. Days Alive and Free of Invasive Mechanical Ventilation Through Day 28

    Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome.

    Time frame: From randomization through day 28

Secondary outcomes

  1. All-Cause Mortality at Day 28

    Percentage of participants who die from any cause within 28 days after randomization.

    Time frame: From randomization through day 28

  2. Duration of Invasive Mechanical Ventilation

    Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis.

    Time frame: From randomization until successful liberation, death, or day 90

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Aug 2028
CompletionEst.
Oct 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938931
Lead sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Collaborators
Hospital Universitario Central de Asturias, SEMICYUC
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Dr Laura Amado-Rodríguez
Contact
laura.amado@sespa.es
+34 985108000
Dr Miguel Ángel Rodríguez Yago
Contact
miguelangel.rodriguezyago@gmail.com
+34 985108000
Laura Amado-Rodríguez, MD, PhD
principal investigator · Hospital Universitario Central de Asturias

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion